About US
Contact us
-
Can retooled Pfizer deliver on R&D promises?Pfizer ($PFE) CEO Ian Read is long on promises of a sunny R&D future. But its near-term pipeline offers iffy benefits, and Read hasn't clearly outlined his approach to juggling internal research w2012/8/2
-
FDA nixes new gout use for Regeneron's ArcalystThe FDA dashed Regeneron's ($REGN) immediate hopes for a vast expansion of its anti-inflammatory drug Arcalyst. The drugmaker had been aiming to market Arcalyst to prevent gout flare-ups, but the agen2012/8/1
-
Bayer profits hit by $500M charge for Yaz/Yasmin lawsuitsBayer set aside $500 million to cover litigation over the Yaz and Yasmin birth control pills, after FDA added blood-clot warnings to their labels in April. Meanwhile, the company's second-quarter numb2012/8/1
-
Europeans notch approvals for Vertex, Novartis drugsThe European Commission has opened the gates for another round of drug launches. Regulators gave their final blessing to Vertex Pharmaceuticals' ($VRTX) cystic fibrosis treatment Kalydeco, Almirall's2012/7/31
-
SFDA issues the Second Summary of Announcements of Illegal Drug, Medical Device, and Health Food Advertisements in 2012On July 20, 2012, the State Food and Drug Administration (SFDA) issued the Second Summary of Announcements of Illegal Drug, Medical Device, and Health Food Advertisements in 2012.2012/7/31
-
Regeneron expanding as its sees higher sales with EyleaRegeneron Pharmaceuticals ($REGN) is expecting a surge of sales of its eye drug Eylea and is expanding production in preparation. The New York company says it is plowing $75 million into its plant in2012/7/30
-
With FDA panel nod, ThromboGenics closer to first potential drugThromboGenics came closer to having its first approved drug on the U.S. market, gaining an FDA advisory committee recommendation for its lead drug candidate, ocriplasmin, for combatting vision-impairi2012/7/30
-
Merck earnings down, but strength surprises Wall StreetSales of Merck's ($MRK) asthma drug Singulair were up 5.7%. Its diabetes drug Januvia grew 36% to $1.06 billion, and sales of its other key diabetes treatment, Janumet, climbed 28% to $411 million.2012/7/27
-
Amarin prepared for aggressive launch of billion-dollar fish oilYou can buy a twin-pack of Omega 3 fish oil at Walmart for six bucks. Yet Amarin($AMRN) has been so certain that its prescription fish oil will have huge demand that it has spent the last 18 months ge2012/7/27
-
Cancer drugs lift Roche sales as charges slash earningsTwo words explain why Roche might well be the envy of Big Pharma: cancer drugs. The company ($RHHBY) posted sales growth, despite European pricing pressures, to $22.61 billion. Drug revenues beat fore2012/7/26